Charles Schwab
CHRS icon

Charles Schwab’s Coherus Oncology CHRS Stock Holding History

Charles Schwab’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Buy
1,228,069
+72,168
+6% +$118K ﹤0.01% 2836
2026
Q1 		$1.95M Buy
1,155,901
+220,662
+24% +$392K ﹤0.01% 2727
2025
Q4 		$1.33M Sell
935,239
-57,853
-6% -$84.3K ﹤0.01% 2835
2025
Q3 		$1.63M Buy
993,092
+11,720
+1% +$13K ﹤0.01% 2800
2025
Q2 		$718K Buy
981,372
+30,696
+3% +$26.5K ﹤0.01% 3004
2025
Q1 		$767K Sell
950,676
-26,181
-3% -$30.1K ﹤0.01% 2935
2024
Q4 		$1.35M Buy
976,857
+12,530
+1% +$14.1K ﹤0.01% 2808
2024
Q3 		$1M Buy
964,327
+116,217
+14% +$159K ﹤0.01% 2916
2024
Q2 		$1.47M Buy
848,110
+158,984
+23% +$320K ﹤0.01% 2796
2024
Q1 		$1.65M Sell
689,126
-78,571
-10% -$193K ﹤0.01% 2651
2023
Q4 		$2.56M Buy
767,697
+44,325
+6% +$119K ﹤0.01% 2538
2023
Q3 		$2.71M Buy
723,372
+193,449
+37% +$894K ﹤0.01% 2511
2023
Q2 		$2.26M Buy
529,923
+24,681
+5% +$146K ﹤0.01% 2508
2023
Q1 		$3.46M Sell
505,242
-1,547
-0.3% -$12K ﹤0.01% 2360
2022
Q4 		$4.01M Buy
506,789
+14,446
+3% +$111K ﹤0.01% 2324
2022
Q3 		$4.73M Buy
492,343
+16,346
+3% +$165K ﹤0.01% 2239
2022
Q2 		$3.45M Buy
475,997
+8,492
+2% +$73.8K ﹤0.01% 2354
2022
Q1 		$6.04M Sell
467,505
-7,732
-2% -$98.3K ﹤0.01% 2189
2021
Q4 		$7.58M Buy
475,237
+7,879
+2% +$138K ﹤0.01% 2143
2021
Q3 		$7.51M Sell
467,358
-8,320
-2% -$122K ﹤0.01% 2172
2021
Q2 		$6.58M Buy
475,678
+8,735
+2% +$124K ﹤0.01% 2216
2021
Q1 		$6.82M Sell
466,943
-40,230
-8% -$683K ﹤0.01% 2148
2020
Q4 		$8.81M Sell
507,173
-7,599
-1% -$135K ﹤0.01% 1936
2020
Q3 		$9.44M Sell
514,772
-103,718
-17% -$1.93M ﹤0.01% 1739
2020
Q2 		$11M Sell
618,490
-7,113
-1% -$120K 0.01% 1586
2020
Q1 		$10.1M Sell
625,603
-39,390
-6% -$728K 0.01% 1447
2019
Q4 		$12M Buy
664,993
+285,108
+75% +$5.26M 0.01% 1565
2019
Q3 		$7.7M Buy
379,885
+29,952
+9% +$598K ﹤0.01% 1756
2019
Q2 		$7.73M Buy
349,933
+30,584
+10% +$531K ﹤0.01% 1750
2019
Q1 		$4.36M Buy
319,349
+16,509
+5% +$220K ﹤0.01% 2040
2018
Q4 		$2.74M Buy
302,840
+229
+0.1% +$2.65K ﹤0.01% 2204
2018
Q3 		$4.99M Buy
302,611
+46,397
+18% +$822K ﹤0.01% 2042
2018
Q2 		$3.59M Buy
256,214
+45,144
+21% +$646K ﹤0.01% 2162
2018
Q1 		$2.33M Buy
211,070
+21,373
+11% +$234K ﹤0.01% 2272
2017
Q4 		$1.67M Buy
189,697
+32,016
+20% +$343K ﹤0.01% 2360
2017
Q3 		$2.11M Sell
157,681
-3,685
-2% -$48.7K ﹤0.01% 2266
2017
Q2 		$2.32M Buy
161,366
+27,064
+20% +$521K ﹤0.01% 2177
2017
Q1 		$2.84M Buy
134,302
+14,838
+12% +$365K ﹤0.01% 2048
2016
Q4 		$3.36M Buy
119,464
+5,631
+5% +$158K ﹤0.01% 1938
2016
Q3 		$3.05M Buy
113,833
+7,496
+7% +$204K ﹤0.01% 1921
2016
Q2 		$1.8M Buy
106,337
+55,566
+109% +$1.04M ﹤0.01% 2126
2016
Q1 		$1.08M Buy
50,771
+663
+1% +$10.9K ﹤0.01% 2312
2015
Q4 		$1.15M Buy
50,108
+845
+2% +$21.7K ﹤0.01% 2330
2015
Q3 		$988K Buy
49,263
+2,276
+5% +$69.3K ﹤0.01% 2386
2015
Q2 		$1.36M Buy
46,987
+27,711
+144% +$701K ﹤0.01% 2274
2015
Q1 		$590K Buy
19,276
+5,412
+39% +$140K ﹤0.01% 2574
2014
Q4 		$227K Buy
+13,864
New +$196K ﹤0.01% 2950

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Charles Schwab's CHRS Position: Q2 2026 in Review

Charles Schwab increased its Coherus Oncology (CHRS) stake by 6.2% in Q2 2026, buying an estimated $118K and bringing the position to 1,228,069 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2836.

Charles Schwab first reported a position in CHRS in Q4 2014 and has held it in 47 quarters since. The position peaked at $12M in Q4 2019. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Charles Schwab held 1,228,069 shares of Coherus Oncology worth $1.72M as of Q2 2026.
  • Charles Schwab bought 72,168 Coherus Oncology shares in Q2 2026, an estimated $118K.
  • Coherus Oncology made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2836 holding.
  • Charles Schwab first reported a position in Coherus Oncology in Q4 2014 and has held it in 47 quarters since.
  • Charles Schwab's Coherus Oncology position peaked at $12M in Q4 2019.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.